0
0
Read Time:15 Second
The U.S. Food and Drug Administration has approved an antibody, nirsevimab, which would protect newborns from R.S.V., respiratory syncytial virus. R.S.V. attacks the lung and is the #1 cause of infants, under 1 year old, being taken to hospitals in the United States.
Happy
0 %
Sad
0 %
Excited
0 %
Sleepy
0 %
Angry
0 %
Surprise
0 %
Average Rating
More Stories
NHL Games (4/3/2025)
NBA Games (4/3/2025)
MLB Games (4/3/2025)